Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9329340 | 0.97 | TSHR (0.57) | TSHRPPARDTP53TDP1MEN1 | |
| Oxalic Acid SCHEMBL27997610 | 0.88 | TSHR (0.48) | TSHRPPARDTP53TDP1MEN1 | |
| Oxalic Acid SCHEMBL282616 | 0.88 | TSHR (0.48) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL479207 | 0.78 | PPARD (0.58) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL3485999 | 0.77 | TSHR (0.60) | TSHRPPARDTP53TDP1MEN1 | |
| Hydrochloric Acid SCHEMBL11686519 | 0.76 | PPARD (0.56) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL3780129 | 0.76 | TSHR (0.75) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL5961215 | 0.75 | TSHR (1.00) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL26483 | 0.75 | TSHR (1.00) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL282472 | 0.75 | TSHR (0.67) | TSHRPPARDTP53TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 505 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1155023-B1 | CHELATING COMPOUNDS AND THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO SPA (IT) | 2005-03-02 | — | — | EP | claimed |
| JP-2003518131-A | — | — | 2003-06-03 | — | — | JP | claimed |
| CN-1105117-C | Pharmaceutical aminophosphonic acid derivatives | SYMPHAR SA (CH) | 2003-04-09 | — | — | CN | claimed |
| US-6509324-B1 | Use as contrast agents in magnetic resonance imaging | BRACCO S.P.A. (IT) | 2003-01-21 | — | — | US | claimed |
| US-20030013859-A1 | CHELATING COMPOUNDS, THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO S.P.A. (IT) | 2003-01-16 | — | — | US | claimed |
| EP-1155023-A1 | CHELATING COMPOUNDS AND THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO S.p.A. (IT) | 2001-11-21 | — | — | EP | claimed |
| WO-2001046207-A1 | CHELATING COMPOUNDS, THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO S.P.A. (IT) | 2001-06-28 | — | — | WO | claimed |
| CN-1240451-A | Pharmaceutical aminophosphonic acid derivatives | SYMPHAR SA (CH) | 2000-01-05 | — | — | CN | claimed |
| CN-1193913-A | Compounds and pharmaceutical compositions containing them | SYMPHAR SA (CH) | 1998-09-23 | — | — | CN | claimed |
| US-4022760-A | HORMONES | PARKE, DAVIS & COMPANY (US) | 1977-05-10 | — | — | US | claimed |
| US-4022759-A | HORMONES | PARKE, DAVIS & COMPANY (US) | 1977-05-10 | — | — | US | claimed |
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250241109-A1 | Electron Transporting Self-Assembling Monolayer Compound for Use in Optoelectronic and/or Photoelectrochemical Devices and Manufacture Thereof | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2025-07-24 | — | — | US | disclosed |
| EP-4590099-A1 | ELECTRON TRANSPORTING SELF-ASSEMBLING MONOLAYER COMPOUND FOR USE IN OPTOELECTRONIC AND/OR PHOTOELECTROCHEMICAL DEVICES AND MANUFACTURE THEREOF | Kaunas University of Technology (LT) | 2025-07-23 | — | — | EP | disclosed |
| EP-4566608-A2 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-4022760-A | HORMONES | PARKE, DAVIS & COMPANY (US) | 1977-05-10 | — | — | US | disclosed |
| US-4022760-A | HORMONES | PARKE, DAVIS & COMPANY (US) | 1977-05-10 | — | — | US | disclosed |
| US-4013813-A | AMINOALKYLPHOSPHONIC ACID ESTER-BASED TEXTILE FIRE RETARDANTS | LEBLANC RESEARCH CORPORATION (US) | 1977-03-22 | — | — | US | disclosed |
| US-3962224-A | CHEMICAL INTERMEDIATES FOR ANTIBIOTICS | MERCK & CO., INC. (US) | 1976-06-08 | — | — | US | disclosed |
| US-3947413-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | TSHR 680/4885PPARD 18/4885TP53 3873/4885 |
| US-20030013859-A1 | CHELATING COMPOUNDS, THEIR COMPLEXES WITH PARAMAGNETIC METALS | MPI, SLC39A14, LRPPRC | TSHR 959/4885PPARD 2059/4885TP53 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.